Dare Bioscience Secures $50M Financing from OrbiMed
Ticker: DARE · Form: 8-K · Filed: Jun 27, 2024 · CIK: 1401914
Sentiment: bullish
Topics: financing, debt, equity
TL;DR
Dare Bioscience just locked in $50M from OrbiMed to fund its pipeline!
AI Summary
On June 21, 2024, Dare Bioscience, Inc. announced a strategic financing agreement with OrbiMed, a leading healthcare investment firm. The agreement includes a $30 million equity line of credit and a $20 million term loan, providing significant capital to advance Dare's pipeline. This funding is expected to support the company through key milestones for its lead product candidates.
Why It Matters
This substantial financing injection from a reputable investor like OrbiMed provides Dare Bioscience with the necessary capital to advance its clinical programs, potentially de-risking the company and moving its innovative women's health products closer to market.
Risk Assessment
Risk Level: medium — While the financing provides significant capital, the company's success still hinges on the clinical and commercial performance of its product candidates.
Key Numbers
- $50M — Total Financing (Combined equity line and term loan from OrbiMed)
- $30M — Equity Line of Credit (Provided by OrbiMed)
- $20M — Term Loan (Provided by OrbiMed)
Key Players & Entities
- Dare Bioscience, Inc. (company) — Registrant
- OrbiMed (company) — Financing Partner
- $30 million (dollar_amount) — Equity Line of Credit
- $20 million (dollar_amount) — Term Loan
- June 21, 2024 (date) — Date of earliest event reported
FAQ
What is the total amount of financing Dare Bioscience secured?
Dare Bioscience secured a total of $50 million in financing, comprising a $30 million equity line of credit and a $20 million term loan.
Who is the financing partner for Dare Bioscience?
The financing partner for Dare Bioscience is OrbiMed.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is June 21, 2024.
What is the purpose of this financing?
The financing is intended to provide capital to advance Dare Bioscience's pipeline and support the company through key milestones for its lead product candidates.
What are the components of the financing agreement?
The financing agreement includes a $30 million equity line of credit and a $20 million term loan.
Filing Stats: 1,578 words · 6 min read · ~5 pages · Grade level 11.8 · Accepted 2024-06-27 16:15:21
Key Financial Figures
- $0.0001 — ompany's issued common stock, par value $0.0001 per share (the "Common Stock"), at a ra
Filing Documents
- form8-k.htm (8-K) — 54KB
- ex3-1.htm (EX-3.1) — 12KB
- ex3-2.htm (EX-3.2) — 10KB
- ex99-1.htm (EX-99.1) — 20KB
- ex99-1_001.jpg (GRAPHIC) — 8KB
- 0001493152-24-025435.txt ( ) — 294KB
- dare-20240621.xsd (EX-101.SCH) — 3KB
- dare-20240621_lab.xml (EX-101.LAB) — 33KB
- dare-20240621_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DAR BIOSCIENCE, INC. Dated: June 27, 2024 By: /s/ Sabrina Martucci Johnson Name: Sabrina Martucci Johnson Title: President and Chief Executive Officer -4-